Leerink Partnrs Has Pessimistic Outlook of ALGN Q1 Earnings

Align Technology, Inc. (NASDAQ:ALGN) – Stock analysts at Leerink Partnrs decreased their Q1 2025 earnings per share estimates for Align Technology in a research note issued on Wednesday, April 9th. Leerink Partnrs analyst M. Cherny now expects that the medical equipment provider will post earnings of $1.51 per share for the quarter, down from their prior estimate of $1.56. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Align Technology’s current full-year earnings is $7.98 per share. Leerink Partnrs also issued estimates for Align Technology’s FY2028 earnings at $11.35 EPS.

A number of other brokerages have also recently commented on ALGN. Bank of America lifted their price target on Align Technology from $200.00 to $206.00 and gave the stock an “underperform” rating in a research report on Friday, December 13th. Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a research report on Thursday, February 6th. Jefferies Financial Group cut their price target on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Mizuho decreased their price objective on shares of Align Technology from $295.00 to $250.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Finally, Leerink Partners upgraded shares of Align Technology from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $235.00 to $280.00 in a research note on Monday, January 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Align Technology currently has a consensus rating of “Moderate Buy” and a consensus target price of $262.64.

Align Technology Price Performance

Shares of ALGN opened at $164.14 on Friday. The company’s fifty day moving average price is $177.26 and its 200-day moving average price is $207.35. Align Technology has a 1-year low of $141.74 and a 1-year high of $327.49. The firm has a market capitalization of $12.02 billion, a PE ratio of 29.26, a price-to-earnings-growth ratio of 2.24 and a beta of 1.73.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share for the quarter, missing the consensus estimate of $2.43 by ($0.47). Align Technology had a return on equity of 13.84% and a net margin of 10.54%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Nordea Investment Management AB increased its stake in shares of Align Technology by 3.5% in the 4th quarter. Nordea Investment Management AB now owns 273,664 shares of the medical equipment provider’s stock valued at $56,870,000 after purchasing an additional 9,139 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Align Technology by 119.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 169,641 shares of the medical equipment provider’s stock valued at $35,368,000 after purchasing an additional 92,407 shares during the period. Swedbank AB increased its position in shares of Align Technology by 25.0% in the fourth quarter. Swedbank AB now owns 486,267 shares of the medical equipment provider’s stock valued at $101,392,000 after buying an additional 97,152 shares in the last quarter. Principal Securities Inc. raised its stake in shares of Align Technology by 34.5% during the 4th quarter. Principal Securities Inc. now owns 1,881 shares of the medical equipment provider’s stock worth $392,000 after buying an additional 483 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Align Technology by 1.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,799 shares of the medical equipment provider’s stock valued at $1,626,000 after buying an additional 91 shares in the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.